• Home
  • A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.

A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.

Author List
Bardia A, Hurvitz SA, Rugo HS, Brufsky A, Cortes J, Loibl S, Piccart M, Cowden J, Spears P, Carey LA
Publication
Future oncology (London, England)
Publication ID (Profile URL)
https://researcherprofiles.org/profile/225639517
Publication Year
2021
PubMed ID
34467774
Publication Title
Bardia A, Hurvitz SA, Rugo HS, Brufsky A, Cortes J, Loibl S, Piccart M, Cowden J, Spears P, Carey LA. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. Future Oncol. 2021 Oct 01; 17(30):3911-3924.